東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ null ]

切換: 標籤 | MARC模式 | ISBD

Monocarboxylate Transporter 1 modula...

Hong, Candice Sun.

FindBook

Google Book

Amazon

博客來

Monocarboxylate Transporter 1 modulates cancer cell pyruvate export and tumor growth.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Monocarboxylate Transporter 1 modulates cancer cell pyruvate export and tumor growth./
作者:	Hong, Candice Sun.
面頁冊數:	94 p.
附註:	Source: Dissertation Abstracts International, Volume: 77-05(E), Section: B.
Contained By:	Dissertation Abstracts International77-05B(E).
標題:	Pharmacology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3739887
ISBN:	9781339317373

Monocarboxylate Transporter 1 modulates cancer cell pyruvate export and tumor growth.
Hong, Candice Sun.

Monocarboxylate Transporter 1 modulates cancer cell pyruvate export and tumor growth. - 94 p.

Source: Dissertation Abstracts International, Volume: 77-05(E), Section: B.

Thesis (Ph.D.)--University of California, Los Angeles, 2016.

Many cancers rely on glycolytic metabolism to fuel rapid proliferation. This has spurred interest in designing drugs that target tumor glycolysis such as AZD3965, a small molecule inhibitor of Monocarboxylate Transporter 1 (MCT1) currently undergoing Phase I evaluation for cancer treatment. Since MCT1 mediates proton-linked transport of monocarboxylates such as lactate and pyruvate across the plasma membrane (Halestrap and Meredith, 2004), AZD3965 is thought to block tumor growth through disruption of lactate transport and glycolysis. Here we show that MCT1 inhibition impairs proliferation of glycolytic breast cancer cells that express MCT4 via disruption of pyruvate rather than lactate export. We found that MCT1 expression is elevated in glycolytic breast tumors and cell lines as well as in malignant breast and lung tissues. High MCT1 expression predicts poor prognosis in breast and lung cancer patients. Stable knockdown and AZD3965-mediated inhibition of MCT1 promote oxidative metabolism. Acute inhibition of MCT1 reduces pyruvate export rate but does not consistently alter lactate transport or glycolytic flux in breast cancer cells that also express MCT4. Despite the lack of glycolysis impairment, MCT1 loss-of-function decreases breast cancer cell proliferation and blocks growth of mammary fat pad xenograft tumors. Our data suggest that MCT1 expression is elevated in glycolytic cancers to promote pyruvate export, which when inhibited enhances oxidative metabolism and reduces proliferation. This study presents an alternative molecular consequence of MCT1 inhibitors that further supports their use as anti-cancer therapeutics.

ISBN: 9781339317373Subjects--Topical Terms:

634543
Pharmacology.

Monocarboxylate Transporter 1 modulates cancer cell pyruvate export and tumor growth.
LDR:02542nmm a2200265 4500 001 2074354
005 20160926125820.5
008 170521s2016 ||||||||||||||||| ||eng d
020 $a 9781339317373
035 $a (MiAaPQ)AAI3739887
035 $a AAI3739887
040 $a MiAaPQ $c MiAaPQ
100 1 $a Hong, Candice Sun. $3 3189669
245 1 0 $a Monocarboxylate Transporter 1 modulates cancer cell pyruvate export and tumor growth.
300 $a 94 p.
500 $a Source: Dissertation Abstracts International, Volume: 77-05(E), Section: B.
500 $a Adviser: Heather R. Christofk.
502 $a Thesis (Ph.D.)--University of California, Los Angeles, 2016.
520 $a Many cancers rely on glycolytic metabolism to fuel rapid proliferation. This has spurred interest in designing drugs that target tumor glycolysis such as AZD3965, a small molecule inhibitor of Monocarboxylate Transporter 1 (MCT1) currently undergoing Phase I evaluation for cancer treatment. Since MCT1 mediates proton-linked transport of monocarboxylates such as lactate and pyruvate across the plasma membrane (Halestrap and Meredith, 2004), AZD3965 is thought to block tumor growth through disruption of lactate transport and glycolysis. Here we show that MCT1 inhibition impairs proliferation of glycolytic breast cancer cells that express MCT4 via disruption of pyruvate rather than lactate export. We found that MCT1 expression is elevated in glycolytic breast tumors and cell lines as well as in malignant breast and lung tissues. High MCT1 expression predicts poor prognosis in breast and lung cancer patients. Stable knockdown and AZD3965-mediated inhibition of MCT1 promote oxidative metabolism. Acute inhibition of MCT1 reduces pyruvate export rate but does not consistently alter lactate transport or glycolytic flux in breast cancer cells that also express MCT4. Despite the lack of glycolysis impairment, MCT1 loss-of-function decreases breast cancer cell proliferation and blocks growth of mammary fat pad xenograft tumors. Our data suggest that MCT1 expression is elevated in glycolytic cancers to promote pyruvate export, which when inhibited enhances oxidative metabolism and reduces proliferation. This study presents an alternative molecular consequence of MCT1 inhibitors that further supports their use as anti-cancer therapeutics.
590 $a School code: 0031.
650 4 $a Pharmacology. $3 634543
690 $a 0419
710 2 $a University of California, Los Angeles. $b Pharmacology 0645. $3 3189670
773 0 $t Dissertation Abstracts International $g 77-05B(E).
790 $a 0031
791 $a Ph.D.
792 $a 2016
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3739887